Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En fas 2A-studie av ett nytt antimalariemedel Pyrrolidinamid hos vuxna patienter med okomplicerad P. Falciparum-malaria

6 november 2026 uppdaterad av: GlaxoSmithKline

En fas 2A-studie för att utvärdera säkerheten, tolerabiliteten och farmakokinetiken hos ett nytt antimalariamedel från pyrrolidinamidgruppen vid olika doser och doseringslängder, hos vuxna patienter med okomplicerad P. falciparum-malaria

The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

70

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Lambaréné, Gabon
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Rella Zoleko Manego
    • Tororo
      • Kampala, Tororo, Uganda, 749
        • Rekrytering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Adoke Yeka

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Male and female patients aged 18 to 65 years.

  • Presence of malaria due to mono-infection with P. falciparum confirmed by:

    • Fever, as defined by axillary temperature >=37.5°C or oral/tympanic temperature >=38°C and,
    • Microscopically confirmed P. falciparum malaria parasite mono-infection,
    • A parasite count between 2,000 to 60,000 asexual parasite count/µL of blood for P. falciparum.
  • Have a BMI between >=18 and <=30 kg/m2.

  • Able to swallow oral medication.

  • Signed informed consent, acknowledging understanding and willingness to comply with the requirements of the study. If the patient is unable to write, thumb print consent, signed by an impartial witness is permitted according to local ethical considerations.

  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

    • Is a woman of non-childbearing potential (WONCBP) or
    • Is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method, from Study Day 1, and during the study intervention period (40 +/-3 days).

Exclusion Criteria:

  • Patients with signs and symptoms of severe/complicated malaria according to the WHO 2024 Criteria.
  • Mixed Plasmodium infection, i.e., infection with more than one malaria (plasmodium) species (by microscopy; participant to be withdrawn from study treatment if PCR subsequently indicates presence of mixed infection).
  • Abnormal values: QTcF >450 msec or QTcF >480 msec for patients with bundle branch block.
  • Any clinically significant ECG abnormalities at Screening unrelated to malaria (including but not limited to, second degree AV block (Mobitz Type 2), complete heart block, ST changes, atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, prolonged QT interval.
  • History of malignancy (or current malignancy) of any organ system (other than localized carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • Creatinine >=2 x ULN.
  • Significant illness within two weeks prior to screening.
  • Positive HIV antibody test at screening, or history of HIV infection based on past positive test result, clinical record or current treatment.
  • Severe vomiting, defined as more than 3 times in the 24 hours before screening or inability to tolerate oral treatment.
  • Severe diarrhoea defined as more than 3 watery stools per day in the 24 hours before screening.
  • Known history or evidence (based on clinical examination or investigation) of uncontrolled active cardiovascular disease (including hypertension), respiratory disease (including active tuberculosis even if treatment is ongoing), liver cirrhosis or liver disease (based on prior investigation, clinical signs and/or interpretation of liver enzymes), other active hepatic, renal, gastrointestinal, immunological, neurological, endocrine, infectious, or psychiatric disease.
  • Anaemia (Hb <=8.0g/dl) or known clinically important chronic underlying haematological disease such as sickle cell disease at screening.
  • Significant chronic medical conditions which in the opinion of the investigator preclude enrolment into the study.
  • Have received any antimalarial treatment in the preceding 6 weeks (see Section 6.10), as determined by history or medical record.
  • Prior enrolment in this study and receipt of treatment with GSK3772701.
  • Use of other investigational drugs at the time of enrolment, or within 6 weeks, or 5 half-lives prior to enrolment into this study, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations.
  • History of hypersensitivity to the study drug or drug formulation and capsule (Hypromellose (hydroxypropyl methylcellulose)) constituents.
  • History of drug or alcohol abuse within 3 months prior to dosing, or clinical evidence of such abuse.
  • Participants who in the opinion of the Investigator are unsuitable for participation in the study or cannot be enrolled due to logistical reasons.
  • ALT >2.0 x ULN.
  • Total bilirubin >1.5 x ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is <=1.5xULN.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.

Note: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.

• Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.

Note: Test is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Cohort 1_Single Dose

Participants receive a single GSK3772701 600 mg dose on Day 1.

A 600 mg dose of GSK3772701 administered orally, as 4 capsules of 150 mg.

Experimentell: Cohort 2_ Single Dose

Participants receive a single GSK3772701 900 mg dose on Day 1.

A 900 mg dose of GSK3772701 administered orally, as 6 capsules of 150 mg.

Experimentell: Cohort 3_ Repeat Dose

Participants receive a daily 150 mg dose of GSK3772701 on Day 1 and Day 2.

A daily 150 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 1 capsule.

Experimentell: Cohort 4_ Repeat Dose

Participants receive a daily 400 mg dose of GSK3772701 on Day 1 and Day 2.

A daily 400 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 2 capsules of 150 mg and 1 capsule of 100 mg.

Experimentell: Cohort 5_ Repeat Dose

Participants receive a daily 50 mg dose of GSK3772701 on Day 1, Day 2 and Day 3.

A daily 50 mg dose of GSK3772701 administered orally on Day 1, Day 2 and Day 3, as 1 capsule.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of participants with serious adverse events (SAEs) overall, treatment related, and by severity
Tidsram: From the date of informed consent signing (up to 24 hours prior to Day 1) up to Day 40 (end of the follow-up period)

A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant; abnormal pregnancy outcomes; or any other situation according to medical or scientific judgment. The intensity of SAEs is assessed as per the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity. Any = occurrence of the event regardless of intensity grade and treatment relationship. Treatment related = occurrence of the event which, in the investigator's opinion, is related to the administered treatment regardless of the intensity grade.

From the date of informed consent signing (up to 24 hours prior to Day 1) up to Day 40 (end of the follow-up period)
Number of participants with non-serious AEs overall, treatment related, and by severity
Tidsram: From Day 1 up to Day 40

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of non-serious AEs is assessed using the DAIDS criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity. Any = occurrence of the event regardless of intensity grade and treatment relationship. Treatment related = occurrence of the event which, in the investigator's opinion, is related to the administered treatment regardless of the intensity grade.

From Day 1 up to Day 40

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Maximal observerad koncentration (Cmax) av GSK3772701
Tidsram: Från dag 1 till dag 7
Från dag 1 till dag 7
Area under the concentration (AUC) - time curve (AUC[0-t]) of GSK3772701
Tidsram: From Day 1 to Day 7

AUC(0-t) is defined as the area under the concentration-time curve from time zero to the time of the last evaluable concentration.

From Day 1 to Day 7
AUC(0-t) extrapolated to infinity (AUC[0-inf]) of GSK3772701
Tidsram: From Day 1 to Day 7

AUC(0-inf) is defined as the area under the concentration-time curve extrapolated to infinity calculated as: . AUC(0-inf) = AUC(0-t) + C(t) / λz.

From Day 1 to Day 7
Time to maximum observed drug concentration (Tmax) of GSK3772701
Tidsram: From Day 1 to Day 7

Tmax is defined as time to reach the Cmax.

From Day 1 to Day 7
Apparent terminal half-life (t1/2) of GSK3772701
Tidsram: From Day 1 to Day 7

Apparent terminal phase half-life in plasma (and blood), calculated as loge (2)/λz.

From Day 1 to Day 7
Trough concentration (Ctau) of GSK3772701 following multiple dose administration
Tidsram: From Day 2 to Day 7

Ctau is defined as the trough/pre-dose concentration after dosing interval, tau.

From Day 2 to Day 7
Observed accumulation ratio (R) of GSK3772701 for AUC [AUC(Ro)] following multiple dose administration
Tidsram: From Day 2 or Day 3 to Day 7, compared to Day 1

AUC-tau (Ro) is defined as the accumulation ratio for AUC(0-tau) comparing last day of dosing to Day 1.

From Day 2 or Day 3 to Day 7, compared to Day 1
Observed accumulation ratio of GSK3772701 based on Cmax (RCmax) following multiple doses
Tidsram: From Day 2 or Day 3 to Day 7, compared to Day 1

Cmax (RCmax) is defined as the accumulation ratio for Cmax comparing last day of dosing to Day 1.

From Day 2 or Day 3 to Day 7, compared to Day 1

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 oktober 2026

Primärt slutförande (Beräknad)

8 oktober 2027

Avslutad studie (Beräknad)

8 oktober 2027

Studieregistreringsdatum

Först inskickad

16 april 2026

Först inskickad som uppfyllde QC-kriterierna

16 april 2026

Första postat (Faktisk)

22 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer tohttps://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Tidsram för IPD-delning

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Kriterier för IPD Sharing Access

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera